Revelation Biosciences Stock Total Debt
| REVB Stock | USD 4.18 0.13 3.02% |
Revelation Biosciences fundamentals help investors to digest information that contributes to Revelation Biosciences' financial success or failures. It also enables traders to predict the movement of Revelation Stock. The fundamental analysis module provides a way to measure Revelation Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Revelation Biosciences stock.
Revelation |
Revelation Biosciences Company Total Debt Analysis
Revelation Biosciences' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Revelation Biosciences Total Debt | 5.56 M |
Most of Revelation Biosciences' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Revelation Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Revelation Biosciences has a Total Debt of 5.56 M. This is 99.8% lower than that of the Biotechnology sector and 98.29% lower than that of the Health Care industry. The total debt for all United States stocks is 99.9% higher than that of the company.
Revelation Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Revelation Biosciences' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Revelation Biosciences could also be used in its relative valuation, which is a method of valuing Revelation Biosciences by comparing valuation metrics of similar companies.Revelation Biosciences is currently under evaluation in total debt category among its peers.
Revelation Fundamentals
| Return On Equity | -2.7 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | (4.29 M) | ||||
| Shares Outstanding | 522.28 K | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 11.80 % | ||||
| Number Of Shares Shorted | 63.43 K | ||||
| Price To Earning | 8.69 X | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 2.88 X | ||||
| Gross Profit | 90.91 M | ||||
| EBITDA | (95.21 K) | ||||
| Net Income | (120.25 K) | ||||
| Cash And Equivalents | 3.48 M | ||||
| Cash Per Share | 0.15 X | ||||
| Total Debt | 5.56 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 0.68 X | ||||
| Book Value Per Share | 9.97 X | ||||
| Cash Flow From Operations | (7.29 M) | ||||
| Short Ratio | 0.13 X | ||||
| Earnings Per Share | (280.48) X | ||||
| Target Price | 170.73 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 2.18 M | ||||
| Total Asset | 12.21 M | ||||
| Retained Earnings | (25.47 M) | ||||
| Working Capital | 6.58 M | ||||
| Net Asset | 12.21 M |
About Revelation Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Revelation Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Revelation Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Revelation Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out Revelation Biosciences Piotroski F Score and Revelation Biosciences Altman Z Score analysis. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.